UniQure Stock Drops After Huntington's Drug Results Disappoint at 4-Year Mark

By Kelly CloonanShares of uniQure slid after patients treated with its Huntington's disease drug in a recent study no longer showed a statistically significant slowdown in disease-induced decline after four years.The stock fell 47% to $20.91 in premarket trading on Tuesday. As of Monday's market cl…